secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001396814-23-000085
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira appoints Frank D. Lee as CEO effective Jan 2, 2024; Stack retires to advisory role
--------------------------------------------------------------------------------

- Frank Lee named CEO and Board member, effective Jan 2, 2024; prior CEO of Forma Therapeutics.
- David Stack retires as CEO and Chairman, remains as advisor through August 2025.
- Paul Hastings, Lead Independent Director, elected Chair of the Board effective Jan 2, 2024.
- Lee's compensation: $900k base salary, 85% bonus target, 692,512 options, 99,520 RSUs as inducement awards.
- Pacira Amended 2014 Inducement Plan to reserve 817,093 shares; term extended to Dec 20, 2033.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/0001396814-23-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000085/pcrx-20231220.htm
  HTML page:      https://secwatch.observer/filing/0001396814-23-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer